Search results
The comprehension of glycoprotein structure and functions are very essential and inevitable to enhance the knowledge of glycoengineering for glycoprotein-based therapeutics as may be required for the treatment of diabetes mellitus and its associated complications.
- The Significance of Anti-Beta-2-Glycoprotein I Antibodies in ...
Beta-2-glycoprotein I (B2GPI) binds anionic phospholipids...
- The Significance of Anti-Beta-2-Glycoprotein I Antibodies in ...
Beta-2-glycoprotein I (B2GPI) binds anionic phospholipids and is considered to be the predominant antigen in APS and antibodies against B2GPI (anti-B2GPI) are recognised in the laboratory criteria for APS diagnosis.
1 lis 2020 · The major drug therapy for type II DM comprises of insulin secretagogues, biguanides, insulin sensitizers, alpha glucosidase inhibitors, incretin mimetics, amylin antagonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors.
5 gru 2014 · This chapter reviews several important themes pertaining to the antiphospholipid syndrome (APS), including a description of the clinical features, a discussion of the main autoantigen, beta 2-glycoprotein I (β 2 GPI), and insights into the characteristics of the pathogenic anti-β 2 GPI autoantibodies. Evidence-based considerations for when to ...
12 lip 2012 · In this overview, we will summarize our knowledge on the etiology of the autoantibodies, and we will discuss the evidence that identify autoantibodies against β 2 -glycoprotein I as the culprit of APS. Topics: autoantibodies, glycoprotein, antiphospholipid antibodies, antibodies, thrombosis, thrombus, phospholipids.
1 sie 2019 · Chemiluminescent assays (CLIA) can be used as an alternative to ELISA. Recent advances allow us to propose antibodies targeting beta-2-glycoprotein I (β 2 -GPI) as the most specific antibodies associated with anti-phospholipid syndrome (APS).
25 cze 2021 · Peptide-based GLP-1 receptor agonists have acclaimed a prominent role in the treatment of type 2 diabetes, as effective regarding glycaemic control as (basal) insulin, with the added benefits of not provoking hypoglycaemic episodes, reducing bodyweight, and preventing clinical cardiovascular events like myocardial infarction, stroke, and ...
